Article Correctness Is Author's Responsibility: Studies Halted for Alzheimer’s Candidate Atabecestat Due to Safety Concerns

The article below may contain offensive and/or incorrect content.

Janssen announced that the Company will no longer continue studying atabecestat, an investigational treatment for asymptomatic patients at risk for developing Alzheimer disease.